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Vitamin D analogues upmregulate p21 and p27 during
growth inhibition of pancreatic cancer cell lines
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Summary To obtain information regarding the growth-inhibitory effect of 1,25-dihydroxyvitamin D3 and its non-calcaemic analogue 22-oxa-
1,25-dihydroxyvitamin D3 on pancreatic cancer cell lines, differences in the effects of Gl-phase cell cycle-regulating factors were studied in
vitamin D-responsive and non-responsive cell lines. Levels of expression of cyclins (D1, E and A), cyclin-dependent kinases (2 and 4) and
cyclin-dependent kinase inhibitors (p21 and p27) were analysed by Western blotting after treatment with these compounds. In the responsive
cells (BxPC-3, Hs 700T and SUP-1), our observations were: (1) marked up-regulation of p21 and p27 after 24 h treatment with 10-7 mol 1-'
1,25-dihydroxyvitamin D3 and 22-oxa-1,25-dihydroxyvitamin D3; and (2) marked down-regulation of cyclins, cyclin-dependent kinases and
cyclin-dependent kinase inhibitors after 7 days' treatment. In non-responsive cells (Hs 766T and Capan-1), no such changes were observed.
In conclusion, vitamin D analogues up-regulate p21 and p27 as an early event, which in turn could block theG,/S transition and induce growth
inhibition in responsive cells.
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1,25-Dihydroxyvitamin D3 (calcitriol, 1,25D3) is well known to
induce differentiation ofleukaemic cells (Abe et al, 1981; Honma
etal, 1983). This differentiation is linked to exit from the cell cycle
atthe restriction (R) point in lateGI stage, resulting in growth inhi-
bition, which suggests a new strategy for cancer therapy (Pardee,
1974). Antiproliferative effects of 1,25D3 on several types of
adenocarcinoma cells have also been reported (Frampton et al,
1983; Eisman et al, 1987; Shabahang et al, 1993; Peehl et al,
1994). Recently, non-calcaemic and more potent differentiation-
inducing analogues of vitamin D have been synthesized to facili-
tate the clinical application of such compounds (Abe et al, 1987,
1991; Anzano et al, 1994; Wali et al, 1995). Among these, 22-oxa-
1,25-dihydroxyvitamin D3 (22-oxa-calcitriol, OCT) has been
shown to have a potent antiproliferative effect on breast cancer
cells inoculated into athymic mice without inducing hypercal-
caemia (Abe et al, 1991; Abe-Hashimoto, 1993). Our previous
study showed that OCT as well as 1,25D3 inhibited the prolifera-
tion of some pancreatic cancer cell lines, which was linked toGi-
phase cell cycle arrest and cell differentiation (Kawa et al, 1996).
This cellular differentiation is thought to be closely associated
with factors regulating theG, phase ofthe cell cycle (Halevy et al,
1995; Skapek et al, 1995; Parker et al, 1995), and the cascades of
these cell cycle signals may be induced by cyclin-dependent
kinase inhibitors (CDKI) such asp16, p21 and p27 (El-Deiry et al,
1993; Gu et al, 1993; Harper et al, 1993; Serrano et al, 1993;
Xiong et al, 1993; Polyak et al, 1994). Accordingly, the antiprolif-
erative or differentiation-inducing effects of vitamin D analogues
might be mediated by molecules that regulate the cell cycle ofGI.
Previous reports have suggested a close relationship between the
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differentiation-inducing activity of vitamin D and the network of
cell cycle-regulating agents, such as retinoblastoma (Rb) protein
in keratinocyte (Kobayashi et al, 1993) and p21 and/or p27 in
leukaemic cell lines (Jiang et al, 1994; Steinman et al, 1994; Liu et
al, 1996; Wang et al, 1996).
Therefore, to clarify the precise effects of vitamin D analogues
on cell cycle-regulating agents in pancreatic cancer cell lines, we
studied the differences in levels of expression of cyclins, CDKs
and CDKIs at different times after treatment with two types of
pancreatic cancer cell lines, one responsive and one non-respon-
sive to OCT and 1,25D3. Both types of cell lines have sufficient
vitamin D receptor contents (Kawa et al, 1996), and are moder-
ately to well differentiated, both morphologically and biochemi-
cally (Vila et al, 1995).
MATERIALS AND METHODS
Chemicals and cells
OCT and 1,25D3 were kindly provided by Chugai Pharmaceutical
(Tokyo, Japan) and purchased from Philip Duphar (Amsterdam,
The Netherlands) respectively. The details of the synthetic proce-
dures and characteristics of OCT have been described previously
(Kubodera et al, 1986; Murayama et al, 1986). Stock solutions of
both agents were prepared at a concentration of 1 x 10-3 mol l-1 in
100% ethanol. The final concentration of ethanol in the culture
medium did not exceed 0.01%. Five established pancreatic cancer
cell lines were studied. BxPC-3, Hs 700T, Hs 766T and Capan-1
were obtained from the American Type Culture Collection
(Rockville, MD, USA); SUP-1 was established in our laboratory
from the pleural effusion ofapatient with pancreatic cancer. All of
these cell lines had sufficient vitamin D receptor content as deter-
mined by Scatchard analysis in a previous study (BxPC3, 2743;
Hs 766T, 1397; Hs 700T, 800; Capan-1, 695; and SUP-1,
670 fmol mg-' DNA-'; Kawa et al, 1996) and were moderately to
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Figure 1 The antiproliferative effects of 1,25D3 (0) and OCT ([:I) on five
pancreatic cancer cell lines at 1 x 10-7 mol I-i, when cells with vehicle came
close to confluency. Cells were continuously exposed to agent, and the
medium was exchanged every 3 days. Mean values ± s.d. of four wells are
indicated as percentages of controls for each cell line
well differentiated, as both morphologically and biochemically
(Vila et al, 1995). Cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum (Gibco, Grand Island,
NY, USA), 0.1 mmol 1-1 glutamine and antibiotics at 370C in a
humidified atmosphere of5% carbon dioxide.
Antibodies
The following polyclonal and monoclonal antibodies were used
for Westemn blotting analysis. Polyclonal antibodies to PCNA
(Dakopatts, Glostrup, Denmark), CDK2 (M2, Santa Cruz), CDK4
(C-22, Santa Cruz) and p27 (C-19, Santa Cruz) were used.
Monoclonal antibodies to cyclin D, (5D4, MBL, Japan), cyclin E
(HE12, Santa Cruz Biotechnology, CA, USA), cyclin A (BF683,
Control
BxPC-3
Hs 766T
G127%
G153%
Santa Cruz), p21 (Clone#70, Transduction Laboratories, KY,
USA) and Rb protein (G3-245, Pharmigen, CA, USA) were used.
Growth inhibition assay
After reaching confluency, cells were washed twice with RPMI-
1640 medium, trypsinized and plated in 24-well plates at a density
of 2 x 103 per well in 1 ml of the same culture medium. OCT or
1,25D3 was added at a concentration of 1 x 10-7 mol 1-1 to the cell
cultures on the second day ofthe experiment, and the cell cultures
were re-fed with fresh culture medium containing OCT and
1,25D3 every 3 days. Growth inhibition was determined by
measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) absorbance ofliving cells, when cells with vehicle
came close to confluency (Kawa et al, 1996). A linear relationship
was found between the absorbance and the cell number that was
between 1 x 104 and 1 x 106 cells per well for each cell line even in
the OCT- or 1,25D3-treated groups. Four wells were used for each
treatment, and experiments were repeated twice.
Flow cytometry
Cells were incubated in culture flasks with 1 x 10-7 mol 1- OCT or
1,25D3 and with vehicle treatment for the same time as for growth
inhibition assay. To reduce the effects ofcontactinhibition, control
cells were adjusted to reach 60-70% confluency at the time of
FACS analysis. Each group ofcells was collected and washed with
phosphate-buffered saline three times. Then, the cells were resus-
pended in a DNA-staining solution containing propidium iodide
(10 mg mi-l) and RNAase (1.8 units pl-). The cells were analysed
with a FACScan flow cytometer equipped with an argon laser
(488 nm, Becton Dickinson Immunocytometry System, Mountain
View, CA, USA). Experiments were repeated three times.
1,25D3
G162%
OCT
G166%
G149% G156%
Figure 2 Representative results of cell cycle analysis of BxPC-3 and Hs 766T cells with 1,25D3 and OCT treatment. Cells were exposed to reagent for the
same period as in the growth inhibition assay, and to reduce the effect of contact inhibition control cells were adjusted to reach 60-70% confluency at the time
of FACS analysis
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Figure 3 Immunoblotting analysis of p27 and p21 in BxPC-3 and Hs 766T cells treated with 1,25D and OCT for the indicated times in hours and days. C,
untreated cells exposed to ethanol vehicle; D and 0, cells treated with
1 x 10-7 mol l-1 1,25D3 and OCT, respectively
Immunoblotting
Cells were cultured with either I0-7 mol 1-1 OCT or 1,25D3 for
various incubation periods, and were collected after trypsin treat-
ment. Collected cells were homogenized, then lysed in 50 ,l ofcell
lysisbuffer [50 mmol 1-1 Tris-HCl, pH 8.0,0.25 mol 1-1 sodium chlo-
ride, 0.5% NP-40, 1 mmol 1-1 polymethyl sulphonyl fluoride (PMSF,
Sigma), 1 mg ml-1 aprotinin (Boehringer Mannheim, Germany),
1 mg ml-1 leupeptin (Boehringer Mannheim), 20 mg ml-1 TPCK
(Boehringer Mannheim)]. Lysates were centrifuged at 13 000g for
20 min at 4°C and the supernatants were stored at -80°C. Extracts
equivalent to 30 ,ig of total protein were separated by SDS-poly-
acrylamide gel electrophoresis (10% acrylamide), followed by equi-
libration of the gel in transfer buffer (20% methanol, 25 mmol 1-1
Tris, 192 mmol 1-1 glycine, pH 8.0) for 30 min. The proteins were
then transferred to supported nitrocellulose membranes (Gibco
BRL, Gaithersburg, MD, USA) at 2400 V min-' with a plate
electrode apparatus (Idea Scientific, Minneapolis, MN, USA). The
filters were blocked in TBST (0.2 mol l-1 sodium chloride,
10 mmol 1-1 Tris, pH 7.4, 0.2% Tween -20), containing 5% non-fat
milk and 0.02% sodium azide for 1 h, followed by incubation with
mouse monoclonal antibodies against human cyclin DI, cyclin E,
cyclin A, p21 or Rb protein or rabbit polyclonal antibodies against
human PCNA, CDK2, CDK4 or p27 (0.1 jig ml-') in TBST
containing 5% non-fat milk. Filters were then incubated with horse-
radish peroxidase-conjugated rabbit anti-mouse Ig or donkey anti-
rabbitIg (1:1000; Amersham, ArlingtonHeights, IL, USA) inTBST
containing 2% non-fat milk. The filters were washed several times
withTBSTbetweeneach step. Boundantibody was detected with an
enhanced chemiluminescence (ECL) system (Amersham, Bucks,
UK) and exposed to radiographic film. The intensity of each band
was measured with a CCD image sensor (densitograph AE-6920-
MF; Atto, Japan), and the ratio of the band density of the treated
group to that of the vehicle group was calculated. The experiments
were repeated at least three times to confirm reproducibility.
RESULTS
Growth inhibition assay and flow cytometry
As shown in Figure 1, significant growth inhibition was observed
in three cell lines, BxPC3, Hs 700T and SUP-1, after treatment
with 1 x 10-7 mol 1-1 OCT and 1,25D3. OCT showed slightly more
potent suppressive effects on BxPC3 and Hs 700T than 1,25D3.
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Figure 4 Densitometric analysis of p21 and p27 Western blotting of BxPC-3 cell. Means ± s.d. of three relative density of each band compared with that of
vehicle treatment are shown chronologically
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3 and 6). In contrast, in two non-responsive cell lines, no marked
changes in expression of any of the antigens examined were
observed after both treatments. The results for Hs 766T are shown
in Figures 3 and 6, in which no bands were observed by cyclin A
staining on the seventh day.
-97
Figure 5 Immunoblotting analysis of retinoblastoma (Rb) protein in BxPC-3
cells treated with 1,25D3 and OCT for the indicated times in hours. C,
untreated cells exposed to ethanol vehicle; D and 0, cells treated with
1 x 10-7mol 1-1 1,25D3 and OCT respectively; ppRb, hyperphosphorylated
form of Rb protein; pRb, hypophosphorylated form of Rb protein
The remaining two cell lines showed no response at any concen-
tration of OCT or 1,25D3. This growth inhibition was linked to
G,-phase cell cycle arrest as indicated by flow cytometry (Figure
2). In OCT- and 1,25D3-responsive BxPC3 cells, the population of
GI phase cells increased after treatment (control 27%, 1,25D3 62%
and OCT 66%), whereas non-responsive Hs 766T cells showed
no changes.
Western blot analysis
Western blot analysis showed marked increases in p21 and
p27 content in responsive cell lines after 24 h treatment.
Representative results for BxPC-3 are shown in Figure 3.
Means ± s.d. of three experiments for densitometry analysis
ofp21 and p27 are shown in Figure 4.
Concomitant with marked induction ofp21 and p27, an increase
in the level of the hypophosphorylated form of Rb protein was
observed in responsive cells after 24 h treatment, with the change
being more prominent with OCT treatment. Representative results
for BxPC-3 are shown in Figure 5.
In both treatment groups marked changes in the cellular
contents of PCNA, cyclins and CDKs were not seen after 1 or 3
days (Figure 6).
On the seventh day of treatment, when prominent growth inhi-
bition was observed in treated groups, cellular contents of PCNA
and otherantigens decreased markedly in responsive cells (Figures
BxPC-3
DISCUSSION
During the growth inhibition of pancreatic cancer cell lines, the
vitamin D analogues OCT and 1,25D3 suppressed the expression
of PCNA and blocked the G1/S transition as revealed by flow
cytometric analysis. Vitamin D analogues markedly increased the
levels of expression of p21 and p27 after 24 h treatment, which
was linked to an increase in the hypophosphorylated form of Rb
protein. These results suggest that the induction ofp21 and p27 is
an early event provoked by vitamin D analogues.
Several studies regarding the growth inhibition or the differenti-
ation of leukaemic cell lines by 1,25D3 have been reported (Jiang
et al, 1994; Steinman et al, 1994; Zhang et al, 1995; Wang et al,
1996; Liu et al, 1996). In HL60 cells (promyelocytic leukaemia
cell line), the up-regulation of p21 was reported after treatment
with 1,25D3 (Jiang et al, 1994; Steinman et al, 1994), but this asso-
ciation could not be confirmed by others (Zhang et al, 1995). In
contrast, p27 was proposed to be a new candidate for the mediator
of 1,25D3 in HL60 cells (Wang et al, 1996). Furthermore, both p21
and p27 were reported to be transcriptionally induced by 1,25D3
during the differentiation of the myelomonocytic cell line U937
(Liu et al, 1996). The present study indicatedthat p21 and p27 play
a majorrole in the growth inhibition ofpancreatic cancer cells that
respond to vitamin D analogues. p16 is also considered to be a
negative regulator of R point control and has been reported to be
induced by 1,25D3 in myelomonocytic leukaemic cells (Liu et al,
1996). Frequent somatic mutations and homozygous deletions
were observed in the p16 gene in pancreatic cancer cells as well as
the responsive cell line BxPC-3 and non-responsive cell lines
Hs766T and Capan-1 (Caldas et al, 1994). LOH and point muta-
tions were observed in the gene encoding p53, which induces the
transcription of p21 gene, in both responsive and non-responsive
cells, BxPC-3 and Capan-1 (Caldas et al, 1994). These results
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Figure 6 Immunoblotting analysis of PCNA, cyclin D, cyclin E, CDK2, CDK4 and cyclin A in BxPC-3 and Hs 766T cells treated with 1,25D3 and OCT for the
indicated times in days (D). C, untreated cells exposed to ethanol vehicle; D and 0, cells treated with 1 x 10-7 mol 1-' 1,25D3 and OCT respectively
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suggest that the growth-inhibitory effects of vitamin D analogues
cannot be mediated by p16 or p53. Vitamin D analogues can use
normal-acting machinery of p21 and p27 for the GI phase of cell
cycle arrest. In non-responsive cells, which have much higher
VDR contents than the responsive cell line SUP-I (Kawa et al,
1996), both OCT and 1,25D3 could not induce such changes, prob-
ably because of the defects in negative regulation of vitamin D
analogues through VDR.
For cells to proceed through the G1/S transition, GI cyclin/CDK
complexes promote the phosphorylation of Rb protein, which
releases the transcription factor E2F, resulting in the expression of
various genes whose products mediate cell cycle progression.
Underthese conditions, the levels ofG1 cyclin/CDK activities must
exceed the threshold ofinhibition setby p21 andp27 (Peters, 1994;
Peter and Herskowitz, 1994). Treatment with vitamin D analogues
seems to alter the balance of these associations and increase the
availability of p21 and p27 to inhibit the G1-cyclin/CDK complex
and induce the hypophosphorylation of Rb protein resulting in
blockage ofthe above sequence. In vitamin D-responsive cell lines,
elevated levels ofp21 and p27 might overcome the activities ofGI
cyclin/CDK complex, which would in tum block G /S transition
and induce exit from cell cycle or growth arrest. Consequently,
such suppressive events may result in the overall suppression of
metabolism and the down-regulation ofcyclins, CDKs and CDKIs
observed on the seventh day oftreatment.
In conclusion, the present study showed that vitamin D
analogues up-regulate p21 andp27 as an early event, which in tum
could block the G1/S transition and lead to growth inhibition in
responsive pancreatic cancer cell lines.
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